Therapeutic area intelligence for Immune Checkpoint Inhibitor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Bristol Myers Squibb →

Assets

YERVOY →

Recent signals(3)

RegulatoryJune 23, 2026

FDA Accepts Supplemental Application for YERVOY (ipilimumab)

The FDA has accepted a supplemental application for YERVOY (ipilimumab) from Bristol Myers Squibb.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for YERVOY (ipilimumab)

The FDA has accepted a supplemental application for YERVOY, an immune checkpoint inhibitor.

Regulatory

June 18, 2026

FDA Accepts Supplement Application for YERVOY (ipilimumab) by Bristol Myers Squibb

The FDA has accepted a supplemental application for YERVOY (ipilimumab) from Bristol Myers Squibb.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.